Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

• Status: Unknown status
• Trial end date: 2020-11-26
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Association of Clinical Trials
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• ≥70 years old and ECOG PS=0-2 or ≥18 years old and ECOG PS=2

• Diagnosed with advanced or recurrent non-squamous NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using RECIST 1.1)

• No prior systemic treatment for non-squamous NSCLC

• Negative in EGFR&ALK&ROS1

• Main organs function is normal

Exclusion Criteria:

• Have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding

• Symptoms of brain metastases cannot be controlled and treated within less than 21 days

• Have participated in other clinical trials of anti-tumor medicine within 4 weeks

• Get any severe diseases or the ones that cannot be controlled